Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 11, Issue 2, 2004, Pages 101-112

  Critchley, Julia A ^a   Unal, Belgin ^b  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cardiovascular disease; Smokeless tobacco; Smoking; Systematic review

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; DATA BASE; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; GLUCOSE INTOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERNET; ISCHEMIC HEART DISEASE; NUTRIENT; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKELESS TOBACCO; STATISTICAL SIGNIFICANCE; SWEDEN; SYSTEMATIC REVIEW;

EID: 2342483038     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjr.0000114971.39211.d7     Document Type: Article

References (60)

1. Department of Health. National Service Framework for Coronary Heart Disease, 2000. http://www.doh.gov.uk/pdfs/chdnsf.pdf.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
3. Shaper AG, Pocock SJ, Walker M, Phillips AN, Whitehead TP, Macfarlane PW. Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health 1985; 39:197-209.
4. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994; 309:901-911.
5. Bottcher M, Falk E. Pathology of the coronary arteries in smokers and non-smokers. J Cardiovasc Risk 1999; 6:299-302.
6. Pech-Amsellem MA, Myara I, Storogenko M, Demuth K, Proust A, Moatti N. Enhanced modifications of low-density lipoproteins (LDL) by endothelial cells from smokers: a possible mechanism of smoking-related atherosclerosis. Cardiovasc Res 1996; 31:975-983.
7. Powell JT. Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc Med 1998; 3:21-28.
8. Tucker LA. Use of smokeless tobacco, cigarette smoking, and hypercholesterolemia. Am J Public Health 1989; 79:1048-1050.
9. Siegel D, Faigeles B. Smoking and socio-economic status in a population-based inner city sample of African-Americans, Latinos and Whites. J Cardiovasc Risk 1996; 3:295-300.
10. Westman EC. Does smokeless tobacco cause hypertension? Southern Med J 1995; 88:716-720.
11. Bolinder GM, Ahlborg BO, Lindell JH. Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large-scale population survey. J Intern Med 1992; 232:327-334.
12. Benowitz N, Jacob P III, Yu L. Daily use of smokeless tobacco: systemic effects. Ann Intern Med 1989; 111:116.
13. Milei J, Grana DR. Mortality and morbidity from smoking-induced cardiovascular diseases: the necessity of the cardiologist's involvement and commitment. Int J Cardiol 1998; 67:95-109.
14. Godtfredsen NS, Prescott E, Osler M, Vestbo J. Predictors of smoking reduction and cessation in a cohort of Danish moderate and heavy smokers. Prev Med 2001; 33:46-52.
15. Fagerstrom KO, Ramstrom L. Can smokeless tobacco rid us of tobacco smoke? Am J Med 1998; 104:501-503.
16. Russell MAH. Smoking, nicotine addiction and lung disease. Eur J Respir Dis 1983; 64:S89:85-89.
17. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Tobacco habits other than smoking; betel quid and areca nut chewing; and some related nitrosamines. Lyon: International Agency for Research on Cancer; 1985.
18. US Department of Health and Human Services. The health consequences of using smokeless tobacco: report of the Advisory Committee to the Surgeon General. NIH Publication No. 86-2874. 1986. Bethesda, Maryland: US Department of Health and Human Services, Public.
19. Rogozinski J. Smokeless tobacco in the Western World: 1550-1950. New York: Praeger; 2002.
20. Ahlbom A, Olsson UA, Pershagen G. Health risks associated with Swedish snus. SoS-rapport 1997:11. (1997 Stockholm report from a symposium on snus arranged by the National Board of Health).
21. Pindborg JJ, Murti PR, Bhonsle RB, Gupta PC. Global aspects of tobacco use and its implications for oral health. In: Gupta PC, Hamner III JE, Murti PR (editors): Control of tobacco-related cancers and other diseases. Proceedings of an international symposium. January 15-19, 1990, Tata Institute of Fundamental Research. Bombay. Oxford: Oxford University Press; 1992.
22. Cancer Statistics Registrations. Registrations of cancer diagnosed in 1994, England and Wales, 2000. London: The Stationery Office. Series MB1 no. 27.
23. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349:1269-1276.
24. Department of Health and Social Services. Report of the Scientific Committee on tobacco and health, 1998. London: The Stationery Office.
25. Peto R, Lopez AD, Boreham J, Thun M, Heath C. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1992; 339:1268-1278.
26. CDC. Annual smoking-attributable mortality, years of potential life lost, and economic costs - USA, 1995-1999. Morbid Mortal Weekly Rep 2002; 51:300-303.
27. Critchley JA, Unal B. Health effects associated with smokeless tobacco use: a systematic review. Thorax 2003; 58:435-443.
28. Westman EC. Does smokeless tobacco cause hypertension? Southern Med J 1995; 88:718-720.
29. Bordia A, Purbiya SL, Khabya BL, Arora SK, Hatimi IH, Singh SV. A comparative study of common modes of tobacco use on pulse, blood pressure, electrocardiogram and blood coagulability in patients with coronary artery disease. J Assoc Physicians India 1977; 25:395-401.
30. Squires WG Jr., Brandon TA, Zinkgraf S, et al. Hemodynamic effects of oral smokeless tobacco in dogs and young adults. Prev Med 1964; 13:195-206.
31. Simon D, Iglauer A. The acute effect of chewing tobacco and smoking in habitual users. Ann NY Acad Sci 1960; 90:119-132.
32. Benowitz N, Porchet H, Sheiner L, et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Pharmacol Ther 1986; 44:23-28.
33. Bolinder G, de Faire U. Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and non-tobacco users. Am J Hypertens 1996; 11:1153-1163.
34. Ksir C, Shank M, Kraemer W, et al. Effects of chewing tobacco on heart rate and blood pressure during exercise. J Sports Med 1986; 26:384-389.
35. Glover E, Edwards S, Christen A, et al. Smokeless tobacco research: an interdisciplinary approach. Health Values 1984; 8:21-25.
36. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003; 290:88-97.
37. Friedenreich CM. Methods for pooled analyses of epidemiologic studies (review). Epidemiology 1993; 4:295-302.
38. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of healthcare interventions. J Epidemiol Commun Health 1998; 52:377-384.
39. Bolinder G, Alfredsson L, Englund A, de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health 1994; 84:399-404.
40. Statistics Sweden. http://www.scb.se/indexeng.asp (2003).
41. Huhtasaari F, Asplund K, Lundberg V, Stegmayr B, Wester PO. Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? BMJ 1992; 305:1252-1256.
42. Huhtasaari F, Lundberg V, Eliasson M, Janlert U, Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction; a population-based study in middle-aged men. J Am Coll Cardiol 1999; 34:1784-1790.
43. Tilgren P, Haglund B, Lundberg M, Romelsjo A. The socio-demographic pattern of tobacco cessation in the 1980s: results from a panel study of living condition surveys in Sweden. J Epidemiol Commun Health 1996; 50:625-630.
44. Eliasson M, Lundblad D, Hagg E. Cardiovascular risk factors in young snuff-users and cigarette smokers. J Intern Med 1991; 230:17-22.
45. Eliasson M, Asplund K, Evrin PE, Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis 1995; 113:41-53.
46. Siegel D, Benowitz N, Emster VL, Grady DG, Hauck WW. Smokeless tobacco, cardiovascular risk factors, and nicotine and cotinine levels in professional baseball players. Am J Public Health 1992; 82:417-421.
47. Khurana M, Sharma D, Khandelwal PD. Lipid profile in smokers and tobacco chewers - a comparative study. J Assoc Physicians India 2000; 48:895-897.
48. Bolinder G, Noren A, de Faire U, Wahren J. Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis 1997; 132:95-103.
49. Blair SN, Kampert JB, Kohl III, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996; 276:205-210.
50. Farrell SW, Kampert JB, Kohl-HW III, et al. Influences of cardiorespiratory fitness levels and other predictors on cardiovascular disease mortality in men. Med Sci Sports Exercise 1998; 30:899-905.
51. Bolinder G, Noren A, Wahren J, de Faire U. Long-term use of smokeless tobacco and physical performance in middle-aged men. Eur J Clin Invest 1997; 27:427-433.
52. Schroeder KL, Chen MS. Smokeless tobacco and blood pressure. N Engl J Med 1985; 312:919.
53. Westman EC, Guthrie GJ. Liquorice, tobacco chewing and hypertension. N Engl J Med 1990; 322:850.
54. Stegmayr B, Johansson I, Huhtasaari F, Moser U, Asplund K. Use of smokeless tobacco and cigarettes - effects on plasma levels of antioxidant vitamins. Int J Vitamin Nutr Res 1993; 63:195-200.
55. Persson PG, Carlsson S, Svanstrom L, Ostenson CG, Efendic S, Grill V. Cigarette smoking, oral moist snuff use and glucose intolerance. J Intern Med 2000; 248:103-110.
56. Lampe FC, Whincup PH, Wannamethee SG, Shaper AG, Walker M, Ebrahim S. The natural history of prevalent ischaemic heart disease in middle-aged men. Eur Heart J 2000; 21:1052-1062.
57. Kozlowski LT, Strasser AA, Giovino GA, Erickson PA, Terva JV. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tobacco Control 2001; 10:201-203.
58. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest 1996; 109:438-445.
59. Silvestry FE, Kimmel SE. Calcium-channel blockers in ischemic heart disease. Curr Opin Cardiol 1996; 11:434-439.
60. Tobacco Advisory Group of the Royal College of Physicians. Protecting smokers, saving lives. The case for a tobacco and nicotine regulatory authority, 2002. Royal College of Physicians.